Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea

Antiviral Chemistry and Chemotherapy

Volumn 13, Issue 5, 2002, Pages 305-314

  Mayhew, C N ^a,b,d   Phillips, J D ^a   Cibull, M L ^b   Elford, H L ^c   Gallicchio, V S ^b  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c Molecules for Health   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Didox; Hydroxyurea; Murine AIDS; Ribonucleotide reductase Inhibitors; Toxicity; Trimidox

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZOHYDROXAMIDOXIME; HYDROXYUREA; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BURST FORMING UNIT E; COLONY FORMING UNIT; COLONY FORMING UNIT GM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EVALUATION; FEMALE; FEMUR; HEMATOCRIT; HEMATOPOIESIS; HISTOPATHOLOGY; IMMUNE DEFICIENCY; INHIBITION KINETICS; LEUKOCYTE; LYMPHOPROLIFERATIVE DISEASE; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RETROVIRUS; SPLEEN WEIGHT; STATISTICAL SIGNIFICANCE; VIRUS INFECTION;

EID: 0037670160     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020201300506     Document Type: Article

References (43)

1. Biron F, Ponceau B, Bouhour D, Boibieux A, Verrier B & Peyramond D (2000). Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 25:329-336.
2. Boelaert JR, Weinberg GA & Weinberg ED (1996). Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infectious Agents & Diseases 5:36-46.
3. Broud D, Piper J, Gallicchio V, Black P, Kunder S, Goldberg G, Elford H, Hall B, van't Riet B, Bacho M, Mayhew C, Papermaster M & Ussery M (1998). Novel ribonucleotide reductase (RR) inhibitors, didox and trimidox, produce antiretroviral effects in the murine acquired immunodeficiency (MAIDS) and in the HIV-infected HuPBMC SCID models. Antiviral Research 37:A58.
4. De Boer RJ, Boucher CA & Perelson AS (1998). Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 12:1567-1570.
5. de Monye C, Karcher DS, Boelaert JR & Gordeuk VR (1999). Bone marrow macrophage iron grade and survival of HIV-seropositive patients. AIDS 13:375-380.
6. Elford HL & van't Riet B (1985). Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives. Pharmacology & Therapeutics 29:239-254.
7. Elford HL, van't Riet B, Wampler GL, Lin AL & Elford RM (1980). Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents. Advances in Enzyme Regulation 19:151-168.
8. Fritzer-Szekeres M, Novotny L, Vachalkova A, Gobl R, Elford HL & Szekeres T (1998). Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase. Advances in Experimental Medicine and Biology 431:599-604.
9. Giacca M, Zanussi S, Comar M, Simonelli C, Vaccher E, De Paoli P & Tirelli U (1996). Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. Journal of Infectious Diseases 174:204-209.
10. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K & Detels R (1993). Elevated levels of CD38+ C138+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes 6:904-912.
11. Grunke M, Dechant C, Low P, Rascu A, Kalden JR & Harrer T (1999). Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes 21:424-426.
12. Hartley JW, Fredrickson TN, Yetter RA, Makino M & Morse HC, III (1989). Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. Journal of Virology 63:1223-1231.
13. Harvie P, Omar RF, Dusserre N, Desormeaux A, Gourde P, Tremblay M, Beauchamp D & Bergeron MG (1996). Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 12:451-461.
14. Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirsch MS, Tebas P, Adams EM, Wheat LJ, Goodwin D, Schnittman S, Holohan MK & Richman DD (2001). Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 15:1379-1388.
15. Jolicoeur P (1991). Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB Journal 5:2398-2405.
16. Klinman DM & Morse HC, III (1989). Characteristics of B cell proliferation and activation in murine AIDS. Journal of Immunology 142:1144-1149.
17. Lafeuillade A, Hittinger G, Chadapaud S, Maillefet S, Rieu A & Poggi (2002). The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and inter-leukin-2 in HIV-infected patients failing protease inhibitor-based combinations. HIV Clinical Trials 3:263-271.
18. Lori F (1999). Hydroxyurea and HIV: 5 years later - from antiviral to immune-modulating effects. AIDS 13:1433-1442.
19. Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C & Lisziewicz J (1999). Immune restoration by combination of a cytostatic, drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Research and Human Retroviruses 15:619-624.
20. Lori F & Lisziewicz J (2000). Role of immune modulation in primary HIV infection. Journal of Biological Regulators and Homeostatic Agents 14:45-48.
21. Maserati R (1999). Hydroxyurea in the treatment of HIV-1 infection: toxicity and side effects. Journal of Biological Regulators and Homeostatic Agents 13:181-185.
22. Mayhew C, Oakley O, Piper J, Hughes NK, Phillips J, Birch NJ, Elford HL, & Gallicchio VS (1997) Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didamosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS). Cellular and Molecular Biology 43:1019-1029.
23. Mayhew CN, Mampuru LJ, Chendil D, Ahmed MM, Phillips JD, Greenberg RN, Elford HL & Gallicchio VS (2002). Suppression of retrovirus-induced immunodeficiency disease (Murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral 56:167-181.
24. Mayhew CN, Phillips JD, Greenberg RN, Birch NJ, Elford HL & Gallicchio VS (1999). In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. Stem Cells 17:345-356.
25. Morse HC, III, Chattopadhyay SK, Makino M, Fredrickson TN, Hugin AW & Hartley JW (1992). Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 6:607-621.
26. Mosier DE (1996). Small animal models for acquired immune deficiency syndrome (AIDS) research. Laboratory Animal Science 46:257-265.
27. Ohnota H, Okada Y, Ushijima H, Kitamura T, Komuro K & Mizuochi T (1990). 3′-Azido-3′-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening. Antimicobial Agents and Chemotherapy 34:605-609.
28. Pace GW & Leaf CD (1995). The role of oxidative stress in HIV disease. Free Radical Biology and Medicine 19:523-528.
29. Palamara AT, Garaci E, Rotilio G, Ciriolo MR, Casabianca A, Fraternale A, Rossi L, Schiavano GF, Chiarantini L & Magnani M (1996). Inhibition of murine AIDS by reduced glutathione. AIDS Research and Human Retroviruses 12:1373-1381.
30. Portnoi D, Stall AM, Schwartz D, Merigan TC, Herzenberg LA & Basham T (1990). Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS. Journal of Immunology 144:1705-1710.
31. Rauko P, Romanova D, Miadokova E, Macakova K, Novotny L, Elford HL & Szekeres T (1997). DNA-protective activity of new ribonucleotide reductase inhibitors. Anticancer Research 17:3437-3440.
32. Rodriguez CG, Vila J, Capurro AF, Maidana MM & Boffo Lissin LD (2000). Combination therapy with hydroxyurea versus without hydroxyurea as first line treatment options for anti-retroviral-naive patients. HIV Clinical Trials 1:1-8.
33. Rutschmann OT, Vernazaa PL, Bucher HC, Opravil M, Ledergerber B, Telenti A, Malinverni R, Bernasconi E, Fagard C, Leduc D, Perrin L & Hirschel B (2000). Long-term hydroxyurea in -combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS 14:2145-2151.
34. Sanne I, Smego RA, Jr, & Mendelow BV (2001). Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem? International Journal of Infectious Disease 5:43-48.
35. Stevenson M, Stanwick TL, Dempsey MP & Lamonica CA (1990). HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO Journal 9:1551-1560.
36. Suruga Y, Makino M, Okada Y, Tanaka H, De Clercq E & Baba M (1998). Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18:316-322.
37. Szekeres T, Gharehbaghi K, Fritzer M, Woody M, Srivastava A, van't Riet B, Jayaram HN & Elford HL (1994). Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology 34:63-66.
38. Szekeres T, Vielnascher E, Novotny L, Vachalkova A, Fritzer M, Findenig G, Gobl R, Elford HL & Goldenberg H (1995). Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase. European Journal of Clinical Chemistry and Clinical Biochemistry 33:785-789.
39. Tihan T, Elford HL & Cory JG (1991). Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime. Advances in Enzyme Regulation 31:71-83.
40. Ussery MA, Wood OL, Broud DD, Bacho MA, Kunder SC, Vona SF, Nielsen CJ & Elford HL (1999). Didox, a novel ribonucleotide reductase inhibitor, is more active than hydroxyurea in HIV-infect-ed HuPBMC SCID mice. Antiviral 41:A48.
41. Youle M, Tyrer M, Fisher M, Lampe F, Wilson D, Ransom D, Story A, Mocroft A, Loveday C, Johnson MA & Phillips AN (2002). Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. Journal of Aquired Immune Deficiency Syndromes 29:58-61.
42. Zala C, Salomon H, Ochoa C, Kijak G, Federico A, Perez H, Montaner JS & Cahn P (2002). Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. Journal of Acquired Immune Deficiency Syndromes 29:368-373.
43. Zinkernagel RM & Hengartner H (1994). T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunology Today 15:262-268.